Abstract:Abstract Background The use of nutraceuticals as adjunctive therapy for ulcerative colitis (UC) is increasingly emerging. HBQ-Complex® (a compound consisting of Hericium erinaceus, berberine, and quercetin), when added to biotin and niacin (a compound called Enteroflegin®), has already shown promising results in ex vivo models of UC as well as in other gastrointestinal disorders such as symptomatic uncomplicated diverticular disease. This multicentric observational retrospective study aimed to weigh the effectiveness and safety of Enteroflegin® in mild-to-moderate UC as adjunctive therapy to oral 5-aminosalicylic acid (5-ASA). Methods Mild-to-moderate UC patients [i.e., with a partial Mayo score (PMS) between 2 and 7] on exclusive therapy with oral 5-ASA (i.e., without taking steroids, biologics, small molecules or other prebiotics/symbiotics/antibiotics) were divided into two groups and evaluated at baseline (T0), after three months (T1) and after six months (T2). One group of patients (G1) took 5-ASA plus two Enteroflegin® tablets for six months, while the other control group underwent only 5-ASA treatment (G2). PMS, faecal calprotectin and 5-ASA dose were collected at each time. Clinical response at T1 and T2 (i.e., reduction in PMS ≥ 2 from baseline) and clinical remission at T1 and T2 (i.e., PMS < 2) were the main outcomes of the study, including compound safety. Results One hundred thirty patients [median age 39.5 (30 - 55), BMI 24.4 (22.8 - 26.4) Kg/m2, median years since UC diagnosis 10 (3.2 - 18.4)] were retrospectively included. In the sample, 51.5% were male, 47.7% had left colitis, 55.4% had proctitis, and 5.4% had pancolitis. 96.2% were on mesalazine therapy. 40.8% of patients had a PMS consistent with moderate activity. The clinical response rate at T2 (69.4% vs 47.5%, p=0.01) and clinical remission at T1 (17.9% vs 4.2%, p=0.029) and T2 (38.9% vs 19.1%, p=0.03) were higher in G1 than in G2 group (Figure A, p < 0.05). The trend in calprotectin reduction was also more favourable for G1 throughout the study (Figure B, p < 0.05). A dosage of 5-ASA > 3.6 g (OR 4.269, 95% CI 1.322 - 13.79; p=0.015) per day, as well as the use of Enteroflegin® (OR 3.303, 95% CI 1.232 - 8.857; p=0.018), resulted as clinical remission at T2 (i.e., six months) predictors. No adverse events were reported. Conclusion The nutraceutical compound Enteroflegin®, when added to standard therapy with oral 5-ASA treatment in patients with mild-to-moderate UC, increased its real-life effectiveness without safety concerns.

Evaluation on Different Dosage of 5-Aminosalicylic Acid Zinc Enteric-Coated Capsule in Treatment of Active Ulcerative Colitis: Multi-Centre Randomized Double-Blind Double-Dummy Controlled Trial

Olsalazine Versus Sulfasalazine in the Treatment of Ulcerative Colitis: Randomized Controlled Clinical Trial

Efficacy and safety of Chinese patent medicine combined with 5-aminosalicylic acid for patients with ulcerative colitis: A network meta-analysis of randomized controlled trials

A multi-center, randomized, single-blind, controlled clinical study on the efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis

[A multi-center randomized double-blinded, placebo-controlled clinical study on efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis of internal dampness-heat accumulation syndrome type]

Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial

Combined Diosmectite and Mesalazine Treatment for Mild-to-moderate Ulcerative Colitis: a Randomized, Placebo-Controlled Study.

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis

The efficacy and safety of mesalazine in the treatment o f inflammatory bowel disease--A nationwide multicenter clinical trial

Use of the Ulcerative Colitis Endoscopic Index of Severity and Mayo Endoscopic Score for Predicting the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis

Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database

Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis

Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis

Synthesis and Evaluation of a Prodrug of 5-Aminosalicylic Acid for the Treatment of Ulcerative Colitis.

5-aminosalicylic acid as a maintenance therapy for ulcerative colitis:an analysis of 114 cases

P992 Nutraceutical treatment based on a multi-compound formulation composed of Hericium erinaceus, berberine, quercetin, niacin, and biotin could improve the oral 5-ASA effectiveness in mild-to-moderate ulcerative colitis: Results from a two-arm multicentric retrospective observational study

N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study

P561 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in Predicting the Therapeutic Effect of Mesalazine in UC Patients

Comparison of the Efficiency of Different Enemas on Patients with Distal Ulcerative Colitis

Effect of Combine Probiotics with Mesalazine on Ulcerative Colitis